Effectiveness of Thrice Weekly Ezetimibe

      Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing. The aim of this study was to examine lipid changes in 33 patients treated with thrice-weekly ezetimibe for ≥1 month, who had pre- and postezetimibe lipid levels and no other concurrent changes in their lipid treatment. Ninety-four percent of the patients were treated with ezetimibe because they experienced myalgias, elevated transaminase levels, or gastrointestinal intolerance with higher doses of other lipid-lowering agents. Total cholesterol decreased by 15% (−36 ± 28 mg/dl, p <0.001) and low-density lipoprotein cholesterol by 20% (−30 ± 25 mg/dl, p <0.001) during 58 ± 50 days of treatment. Most patients (85%) tolerated the treatment, and many (48%) achieved their low-density lipoprotein cholesterol goals. In conclusion, thrice-weekly ezetimibe decreases total and low-density lipoprotein cholesterol and is well tolerated. It is a viable treatment for patients intolerant of other lipid-lowering medications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Spener F.
        Ezetimibe in search of receptor(s)—still a never-ending challenge in cholesterol absorption and transport.
        Biochim Biophys Acta. 2007; 1771: 1113-1116
        • Levy E.
        • Spahis S.
        • Sinnett D.
        • Peretti N.
        • Maupas-Schwalm F.
        • Delvin E.
        • Lambert M.
        • Lavoie M.A.
        Intestinal cholesterol transport proteins: an update and beyond.
        Curr Opin Lipidol. 2007; 18: 310-318
        • Jeu L.
        • Cheng J.W.
        Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.
        Clin Ther. 2003; 25: 2352-2387
        • Gylling H.
        • Miettinen T.A.
        Cholesterol absorption: influence of body weight and the role of plant sterols.
        Curr Atheroscler Rep. 2005; 7: 466-471
        • Miettinen T.A.
        • Gylling H.
        • Strandberg T.
        • Sarna S.
        Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study.
        BMJ. 1998; 316: 1127-1130
        • Jacobson T.A.
        • Armani A.
        • McKenney J.M.
        • Guyton J.R.
        Safety considerations with gastrointestinally active lipid-lowering drugs.
        Am J Cardiol. 2007; 99: 47C-55C
        • Red Book
        Pharmacy's Fundamental Reference.
        in: Thompson Healthcare Inc, Montvale, New Jersey2007: 754